Piper Jaffray maintained ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS ) with a Neutral rating and raised the price target from $9.00 to $11.00. Piper Jaffray said, "The FDA approved KYNAMRO for Homozygous Familial Hypercholesterolemia (HoFH). As expected, the approval comes with a Boxed Warning for liver toxicity and a REMS program.